# Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

> **NCT00705016** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 184 (actual)

## Conditions studied

- Squamous Cell Cancer

## Interventions

- **DRUG:** Cilengitide 2000 mg once weekly
- **DRUG:** Cilengitide 2000 mg twice weekly
- **DRUG:** Cetuximab
- **DRUG:** 5-fluorouracil (5-FU)
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00705016
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-09
- **Final completion:** 2013-06
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2014-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00705016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00705016, "Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00705016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*